4SC achieves hat trick of resminostat successes: RCC, CRC and now Hodgkin’s
This article was originally published in Scrip
German biotechnology firm 4SC will "discuss the path towards registration with the regulatory agencies in the near future" for its oral pan-histone deacetylase (HDAC) inhibitor, resminostat, after the product met the primary endpoint in a Phase II trial in Hodgkin's lymphoma (HL). The company added that it now had the information it needed to initiate the next development steps for the compound.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.